Speratum Biopharma, Inc. (“Speratum”) is an innovative biotechnology company focused on pre-clinical research and development of oligonucleotide therapeutics for the treatment of cancer. The company was founded in 2014 with technologies license from Baylor College of Medicine, which it has combined with proprietary technologies to generate a promising therapeutic platform with broad applicability. Speratum is currently in pre-clinical stages of development for its first therapeutic, a tumor suppressor against pancreatic, ovarian, and other cancers that includes a proprietary RNA interference (RNAi)-inducing mimic of miR-198, a naturally-occurring microRNA involved in the pathogenesis of a number of solid cancers. We combine this therapeutic with a novel delivery system based on Nano-in, our novel polymer that enables the systemic and targeted delivery of nucleic acids both in vitro and in vivo. For further information about our company and our technologies, please contact us info@speratum.com
